目的 探讨复方苦参注射液联合SOX方案治疗晚期胃癌患者的临床疗效。方法 选择2018年3月—2022年2月成都市第五人民医院收治的128例晚期胃癌患者，随机将患者分为对照组和治疗组，每组各64例。对照组给予SOX化疗方案治疗，其中静脉滴注奥沙利铂注射液，130 mg/m²加入250 mL 5%葡萄糖溶液中，第1天持续2 h；同时口服替吉奥胶囊，40 mg/次，2次/d，第1～14天。21 d为1个疗程。治疗组在对照组基础上静脉滴注复方苦参注射液，20 mL/次，用药14 d、停药7 d，3周为1个疗程。两组患者均治疗4个疗程。观察两组患者临床疗效，比较治疗前后两组患者血清肿瘤标志物癌胚抗原（CEA）、糖类抗原19-9（CA19-9）和糖类抗原724（CA724）水平，及T淋巴细胞亚群CD3^＋、CD4^＋、CD8^＋、CD4^＋/CD8^＋水平。结果 治疗后，治疗组的客观缓解率、疾病控制率分别是为78.13%、92.19%，明显高对照组56.25%、79.69%，两组比较差异具有统计学意义（P＜0.05）。治疗后，两组患者CEA、CA19-9、CA724和CD8^＋水平较治疗前均明显降低，而CD3^＋、CD4^＋和CD4^＋/CD8^＋水平明显升高（P＜0.05），且治疗组这些指标明显好于对照组（P＜0.05）结论 复方苦参注射液联合SOX方案治疗晚期胃癌临床疗效较好，能有效降低血清中的肿瘤标志物水平，提升患者的免疫功能。

Objective To investigate the effects of Compound Kushen Injection combined with SOX chemotherapy regimen in treatment of advanced gastric cancer. Methods Patients (128 cases) with advanced gastric cancer in the Fifth People's Hospital of Chengdu from March 2018 to February 2022 were randomly divided into control group and treatment group, 64 cases in each group. Patients in the control group were administered with SOX chemotherapy regimen, 130 mg/m² of Oxaliplatin Injection added into 250 mL 5% glucose solution was injected intravenously for 2 h on the 1st day, and they were po administered with Gimeracil and Oteracil Potassium Capsules 40 mg/time, twice daily for 1 — 14 d, 21 d was a course of treatment. Patients in the treatment group were iv administered with Compound Kushen Injection on the basis of the control group, 20 mL/time, 14 days of medication, 7 days of withdrawal, 3 weeks as a course of treatment. Patients in two groups were treated for 4 courses of treatment. After treatment, the clinical evaluation was evaluated, and the levels of serum tumor markers CEA, CA19-9, and CA724, and the levels of T lymphocyte subsets CD3^＋, CD4^＋, CD8^＋, and CD4^＋/CD8^＋ in two groups before and after treatment were compared. Results After treatment, the objective remission rate and disease control rate of the treatment group were 78.13% and 92.19%, respectively, which were significantly higher than those of the control group 56.25% and 79.69%, and the difference between the two groups was statistically significant (P < 0.05). After treatment, the levels of CEA, CA19-9, CA724, and CD8^＋ in two groups were significantly lower than those before treatment, while the levels of CD3^＋, CD4^＋, and CD4^＋/CD8^＋ were significantly increased (P < 0.05), and these indexes in the treatment group were significantly better than those in the control group (P < 0.05).Conclusion Compound Kushen Injection combined with SOX chemotherapy regimen has a good clinical effect in the treatment of advanced gastric cancer, which can effectively reduce the level of tumor markers in serum and improve the immune function of patients.

R979.1